Cholestech Corporation Receives FDA Clearance for TC/Glucose Panel

Strategic Insights -

Cholestech Corporation, a leading manufacturer of diagnostic testing equipment, has announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market a new diagnostic test panel for the Cholestech L%D%X( System. The TC/Glucose panel is designed to simultaneously measure total cholesterol and glucose levels using only a single drop of whole blood, providing results in less than five minutes.

The TC/Glucose panel is a significant innovation in point-of-care diagnostics, allowing healthcare providers to quickly and efficiently screen for both coronary heart disease and diabetes. This is particularly important given the strong relationship between the two conditions, and the increasing prevalence of diabetes in the population. The panel is also a cost-effective option for healthcare providers, as it eliminates the need to run two separate tests to obtain total cholesterol and glucose results.

Key Takeaways:

  • Cholestech Corporation has received FDA clearance to market the TC/Glucose panel, a diagnostic test panel that simultaneously measures total cholesterol and glucose levels.
  • The TC/Glucose panel requires only a single drop of whole blood and provides results in less than five minutes.
  • The panel is designed to help healthcare providers screen for both coronary heart disease and diabetes, two conditions that are strongly related.
  • The TC/Glucose panel is a cost-effective option for healthcare providers, eliminating the need to run two separate tests to obtain total cholesterol and glucose results.
  • Cholestech Corporation's commitment to promoting accurate preventive health care screening and monitoring of diseases in a point-of-care setting is evident through the development of the TC/Glucose panel.
  • The TC/Glucose panel is the latest addition to Cholestech Corporation's full line of lipid and glucose test cassettes, which includes TC, TC:HDL:GLU, Lipid Profile, and Lipid Profile plus Glucose.
  • The panel is a key component of Cholestech Corporation's efforts to help people lead longer, healthier, and more active lives through accurate preventive health care screening and monitoring.

Statistics:

  • The TC/Glucose panel requires only a single drop of whole blood.
  • Results are provided in less than five minutes.
  • The panel is designed to help healthcare providers screen for both coronary heart disease and diabetes, two conditions that are strongly related.
  • The TC/Glucose panel is a cost-effective option for healthcare providers, eliminating the need to run two separate tests to obtain total cholesterol and glucose results.

Sources:

  • "Cholestech Corporation Receives FDA Clearance to Market TC/Glucose Panel" (Business Wire, April 18, 1995)
  • "Cholestech Corporation Product Line" (Cholestech Corporation)